This study identifies transferrin receptor 1 (TFR1) as the key functional receptor for human parvovirus B19 (B19V), providing a clear molecular target for investigating B19V infection mechanisms and suggesting that the TFR1-VP1u interaction interface could be exploited for antiviral interventions or engineering of viral vectors.
Literature Overview
The article titled 'Transferrin receptor 1 binds human parvovirus B19 VP1u to facilitate entry,' published in Nature Communications, systematically investigates the molecular mechanism by which human parvovirus B19 (B19V) specifically infects erythroid progenitor cells through its unique N-terminal domain of the VP1 capsid protein (VP1u). Using a multidisciplinary experimental approach, the research team identified transferrin receptor 1 (TFR1) as the critical cellular receptor mediating viral endocytosis, resolving the long-standing mystery of the elusive VP1uR.Background Knowledge
Human parvovirus B19 (B19V) is a highly tropic human pathogen that primarily infects erythroid progenitor cells (EPCs) in the bone marrow and fetal liver, causing severe diseases such as erythema infectiosum, aplastic crisis, and intrauterine fetal infection. Its cell-type specificity is determined by the VP1 unique region (VP1u), which mediates erythroid-specific endocytosis. However, the identity of its cellular receptor—long referred to as VP1uR—has remained unknown. Although the glycosphingolipid globoside is known to act as an attachment factor for B19V, its expression is not restricted to erythroid cells and does not determine endocytic specificity. Additionally, AXL was previously proposed as a co-receptor, but it fails to fully explain the restricted tropism. Thus, determining whether TFR1 is the true VP1uR and understanding how it regulates B19V entry have been critical bottlenecks in the field. This study addresses these questions by integrating proximity labeling, functional blocking, and cryo-EM structural analysis to systematically validate the direct interaction between TFR1 and VP1u and its necessity for viral entry.
Research Methods and Experiments
The study used erythroid cell lines such as UT7/Epo and KU812Ep6 as primary models, along with non-erythroid cells (e.g., HeLa, HepG2, Jurkat) as controls, to systematically analyze the cell-specific binding of VP1u. Using an HRP-based proximity labeling technique (SPPLAT), membrane proteins in close proximity to VP1u on the surface of living cells were labeled and identified by mass spectrometry, which revealed TFR1 as the only membrane protein consistently enriched across all replicates. To validate functional relevance, blocking experiments were performed using the anti-TFR1 antibody OKT9. The results showed that OKT9 completely inhibited the binding and internalization of VP1u-conjugated phage (MS2-VP1u), as well as B19V internalization and infection, without affecting initial viral attachment at 4°C, indicating that TFR1 functions at a post-attachment step.
To further confirm direct interaction, bio-layer interferometry (BLI) and mass photometry were employed, demonstrating direct binding between recombinant VP1u and TFR1 with a KD in the micromolar range. The most definitive evidence came from cryo-EM structural analysis: the research team successfully resolved the 2.4 Å structure of the VP1u-TFR1 complex, clearly showing that the receptor-binding domain (RBD) of VP1u binds to the apical domain of TFR1, with each monomer of the VP1u dimer binding to opposite sides of the TFR1 homodimer. Structure-guided mutagenesis further confirmed the role of key residues (e.g., Phe15) in binding, consistent with prior functional studies.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a complete molecular picture of B19V pathogenesis and establishes TFR1 as a promising therapeutic target. For example, peptide- or small molecule-based inhibitors that block the VP1u-TFR1 interaction could be developed for antiviral therapy in high-risk pregnant women or immunocompromised patients. Additionally, the VP1u-TFR1 interaction module could be engineered for targeted delivery, such as modifying AAV vectors to target cells expressing TFR1.
Conclusion
This study integrates proximity labeling, functional blocking, biochemical assays, and structural biology to definitively identify TFR1 as the long-sought receptor VP1uR required for B19V entry, resolving a central question in the field. This discovery not only elucidates the molecular basis of B19V's strict tropism but also provides a new paradigm for understanding how viruses exploit widely expressed receptors to achieve cell-type-specific infection. From a translational perspective, the TFR1-VP1u interaction interface represents a precise target for anti-B19V interventions, particularly relevant for preventing fetal infections. Furthermore, this mechanism can be leveraged to design gene therapy vectors targeting erythroid cells or TFR1-overexpressing tumor cells. Future research may build on this work by generating humanized TFR1 point-mutation models to mimic natural resistance phenotypes or by developing VP1u-derived peptides as competitive inhibitors, advancing from mechanistic insights toward clinical applications.
